139425-04-0Relevant articles and documents
An efficient synthesis of LTD4 antagonist L-699,392
King,Corley,Anderson,Larsen,Verhoeven,Reider
, p. 3731 - 3735 (1993)
-
Synthesis of Montelukast (MK-0476) metabolic oxidation products
Dufresne, Claude,Gallant, Michel,Gareau, Yves,Ruel, Rejean,Trimble, Laird,Labelle, Marc
, p. 8518 - 8525 (2007/10/03)
We report the chemical synthesis of six oxidized derivatives of MK-0476 (Montelukast, L-706631), which have been key tools in the identification of its metabolites. We have prepared three diastereoisomeric pairs of potential oxidative metabolites of MK-0476, starting from the (S)-hydroxy ester 7 in 10 and five steps, and starting from MK-0476 itself in one step. The key benzylic hydroxyl of 1 and 2 was introduced by a bromination and saponification reaction sequence. In the case of the hydroxyl of 3 and 4, the key step was the addition of a hydroxymethyl carbanion equivalent on ketone 20. The two sulfoxide 5 and 6 were prepared by a direct oxidation of MK-0476 with m-chloroperbenzoic acid.
AZABENZIMIDAZOLES IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES
-
, (2008/06/13)
A series of imidazo[4,5-c]pyridines which inhibit platelet activating factor (PAF) and also block leukotriene D4 receptors are useful in treating asthma, arthritis, psoriasis, gastrointestinal distress, myocardial infarction, stroke and shock.